Cargando…

MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated IGHV gene

Detalles Bibliográficos
Autores principales:	Qin, Shu-Chao, Xia, Yi, Miao, Yi, Zhu, Hua-Yuan, Wu, Jia-Zhu, Fan, Lei, Li, Jian-Yong, Xu, Wei, Qiao, Chun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802429/ https://www.ncbi.nlm.nih.gov/pubmed/29242635 http://dx.doi.org/10.1038/s41408-017-0014-y

Ejemplares similares

Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans
por: Xia, Yi, et al.
Publicado: (2014)

HELQ and EGR3 expression correlate with IGHV mutation status and prognosis in chronic lymphocytic leukemia
por: Guo, Chao, et al.
Publicado: (2021)

MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis
por: Vermaat, Joost S., et al.
Publicado: (2020)

Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia
por: Kaufman, Matthew, et al.
Publicado: (2022)

98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia
por: Shi, Ke, et al.
Publicado: (2019)

Genetic and Clinical Characteristics of Korean Chronic Lymphocytic Leukemia Patients with High Frequencies of MYD88 Mutations
por: Ahn, Ari, et al.
Publicado: (2023)

IGHV-associated methylation signatures more accurately predict clinical outcomes of chronic lymphocytic leukemia patients than IGHV mutation load
por: Hussmann, Dianna, et al.
Publicado: (2021)

Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia
por: Heerema, Nyla A., et al.
Publicado: (2020)

Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia
por: Hengeveld, P. J., et al.
Publicado: (2023)

SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas
por: Munshi, Manit, et al.
Publicado: (2020)

Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features
por: Shuai, Wen, et al.
Publicado: (2020)

The Number of Overlapping AID Hotspots in Germline IGHV Genes Is Inversely Correlated with Mutation Frequency in Chronic Lymphocytic Leukemia
por: Yuan, Chaohui, et al.
Publicado: (2017)

Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation
por: Wang, James Q., et al.
Publicado: (2014)

High-resolution melting analysis for rapid and sensitive MYD88 screening in chronic lymphocytic leukemia
por: Jiang, Min, et al.
Publicado: (2019)

High-resolution melting analysis for rapid and sensitive MYD88 screening in chronic lymphocytic leukemia
por: Jiang, Min, et al.
Publicado: (2019)

Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course
por: Bagnara, Davide, et al.
Publicado: (2021)

Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients
por: Chauzeix, Jasmine, et al.
Publicado: (2018)

NOTCH1 Activation Negatively Impacts on Chronic Lymphocytic Leukemia Outcome and Is Not Correlated to the NOTCH1 and IGHV Mutational Status
por: Baldoni, Stefano, et al.
Publicado: (2021)

Schnitzler syndrome associated with MYD88 L265P mutation
por: Goodman, Aaron M., et al.
Publicado: (2019)

MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies
por: Alcoceba, Miguel, et al.
Publicado: (2022)

Otopathogenic Pseudomonas aeruginosa induces MyD88-dependent auditory hair cell damage
por: Mittal, Rahul, et al.
Publicado: (2016)

Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV(mut) and IgHV(unmut) subgroups
por: Burns, A, et al.
Publicado: (2018)

IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study
por: Rotbain, Emelie Curovic, et al.
Publicado: (2020)

Perspectives on Precision Medicine in Chronic Lymphocytic Leukemia: Targeting Recurrent Mutations—NOTCH1, SF3B1, MYD88, BIRC3
por: Putowski, Maciej, et al.
Publicado: (2021)

CD79B and MYD88 Mutations in Splenic Marginal Zone Lymphoma
por: Trøen, Gunhild, et al.
Publicado: (2013)

Immunogenicity of recurrent mutations in MYD88 and EZH2 in non-Hodgkin lymphomas
por: Nielsen, Julie S, et al.
Publicado: (2015)

Simultaneous Presentation of Waldenström's Macroglobulinemia and MYD88 Gene Mutation with Multiple Myeloma
por: Awada, Hassan, et al.
Publicado: (2019)

Celebrating 20 Years of IGHV Mutation Analysis in CLL
por: Chiorazzi, Nicholas, et al.
Publicado: (2020)

Erratum: Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV(mut) and IgHV(unmut) subgroups
por: Burns, A, et al.
Publicado: (2017)

Correction: Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV(mut) and IgHV(unmut) subgroups
por: Burns, A, et al.
Publicado: (2019)

Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21)
por: Qin, Ya-Zhen, et al.
Publicado: (2018)

Lack of Associations between TLR9 and MYD88 Gene Polymorphisms and Risk of Chronic Lymphocytic Leukemia
por: Ali, Yasser B.M, et al.
Publicado: (2017)

PB1869: IGHV REPERTOIRE FEATURES IN KAZAKHSTAN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
por: Klodzinskiy, A., et al.
Publicado: (2022)

MYD88-Mutated Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma as a Distinctive Molecular Subgroup Is Associated with Atypical Immunophenotypes in Chinese Patients
por: Mu, Yafei, et al.
Publicado: (2023)

Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia
por: Maharaj, Dipnarine, et al.
Publicado: (2020)

Preneoplastic somatic mutations including MYD88(L265P) in lymphoplasmacytic lymphoma
por: Rodriguez, Sara, et al.
Publicado: (2022)

Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort
por: Miao, Yi, et al.
Publicado: (2023)

Presence of serum antinuclear antibodies correlating unfavorable overall survival in patients with chronic lymphocytic leukemia
por: Sun, Qian, et al.
Publicado: (2019)

Identification of new putative driver mutations and predictors of disease evolution in chronic lymphocytic leukemia
por: Mosquera Orgueira, Adrián, et al.
Publicado: (2019)

Characteristic immunophenotype and gene co-mutational status orchestrate to optimize the prognosis of CEBPA mutant acute myeloid leukemia
por: Chen, Xinjie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mitksnq6q69ltsabjul4drpe3d